Vaccination against SARS-CoV-2 in Patients with Inflammatory Bowel Diseases: Where Do We Stand?

Crohn’s disease and ulcerative colitis are chronic inflammatory bowel diseases (IBDs). Immunosuppressive medication is the main therapeutic approach to reducing inflammation of the gastrointestinal tract. Immunocompromised patients are more vulnerable to severe courses of illness after infection wit...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Phil-Robin Tepasse, Richard Vollenberg, Tobias Max Nowacki
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	IBD Crohn’s disease ulcerative colitis vaccination SARS-CoV-2 COVID-19 Science Q
Acceso en línea:	https://doaj.org/article/974d936acac9461db59ea627ff5daff4
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:974d936acac9461db59ea627ff5daff4
record_format	dspace
spelling	oai:doaj.org-article:974d936acac9461db59ea627ff5daff42021-11-25T18:11:18ZVaccination against SARS-CoV-2 in Patients with Inflammatory Bowel Diseases: Where Do We Stand?10.3390/life111112202075-1729https://doaj.org/article/974d936acac9461db59ea627ff5daff42021-11-01T00:00:00Zhttps://www.mdpi.com/2075-1729/11/11/1220https://doaj.org/toc/2075-1729Crohn’s disease and ulcerative colitis are chronic inflammatory bowel diseases (IBDs). Immunosuppressive medication is the main therapeutic approach to reducing inflammation of the gastrointestinal tract. Immunocompromised patients are more vulnerable to severe courses of illness after infection with common pathogens. The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is the pathogen of the coronavirus disease 2019 (COVID-19) pandemic. COVID-19 leads to acute respiratory distress syndrome (ARDS) following severe pulmonal damage in a significant number of cases. The worldwide circulation of SARS-CoV-2 has led to major concerns about the management of IBD patients during the pandemic, as these patients are expected to be at greater risk of complications because of their underlying altered immunological condition and immunosuppressive therapies. Vaccination against SARS-CoV-2 is considered the main approach in containing the pandemic. Today, several vaccines have been shown to be highly effective in the prevention of SARS-CoV-2 infection and severe disease course in subjects without underlying conditions in respective registration studies. Patients with underlying conditions such as IBD and/or immunosuppressive therapies were not included in the registration studies, so little is known about effectiveness and safety of SARS-CoV-2 vaccination in immunocompromised IBD patients. This review provides an overview of the recent knowledge about vaccine response in IBD patients after vaccination against SARS-CoV-2.Phil-Robin TepasseRichard VollenbergTobias Max NowackiMDPI AGarticleIBDCrohn’s diseaseulcerative colitisvaccinationSARS-CoV-2COVID-19ScienceQENLife, Vol 11, Iss 1220, p 1220 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	IBD Crohn’s disease ulcerative colitis vaccination SARS-CoV-2 COVID-19 Science Q
spellingShingle	IBD Crohn’s disease ulcerative colitis vaccination SARS-CoV-2 COVID-19 Science Q Phil-Robin Tepasse Richard Vollenberg Tobias Max Nowacki Vaccination against SARS-CoV-2 in Patients with Inflammatory Bowel Diseases: Where Do We Stand?
description	Crohn’s disease and ulcerative colitis are chronic inflammatory bowel diseases (IBDs). Immunosuppressive medication is the main therapeutic approach to reducing inflammation of the gastrointestinal tract. Immunocompromised patients are more vulnerable to severe courses of illness after infection with common pathogens. The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is the pathogen of the coronavirus disease 2019 (COVID-19) pandemic. COVID-19 leads to acute respiratory distress syndrome (ARDS) following severe pulmonal damage in a significant number of cases. The worldwide circulation of SARS-CoV-2 has led to major concerns about the management of IBD patients during the pandemic, as these patients are expected to be at greater risk of complications because of their underlying altered immunological condition and immunosuppressive therapies. Vaccination against SARS-CoV-2 is considered the main approach in containing the pandemic. Today, several vaccines have been shown to be highly effective in the prevention of SARS-CoV-2 infection and severe disease course in subjects without underlying conditions in respective registration studies. Patients with underlying conditions such as IBD and/or immunosuppressive therapies were not included in the registration studies, so little is known about effectiveness and safety of SARS-CoV-2 vaccination in immunocompromised IBD patients. This review provides an overview of the recent knowledge about vaccine response in IBD patients after vaccination against SARS-CoV-2.
format	article
author	Phil-Robin Tepasse Richard Vollenberg Tobias Max Nowacki
author_facet	Phil-Robin Tepasse Richard Vollenberg Tobias Max Nowacki
author_sort	Phil-Robin Tepasse
title	Vaccination against SARS-CoV-2 in Patients with Inflammatory Bowel Diseases: Where Do We Stand?
title_short	Vaccination against SARS-CoV-2 in Patients with Inflammatory Bowel Diseases: Where Do We Stand?
title_full	Vaccination against SARS-CoV-2 in Patients with Inflammatory Bowel Diseases: Where Do We Stand?
title_fullStr	Vaccination against SARS-CoV-2 in Patients with Inflammatory Bowel Diseases: Where Do We Stand?
title_full_unstemmed	Vaccination against SARS-CoV-2 in Patients with Inflammatory Bowel Diseases: Where Do We Stand?
title_sort	vaccination against sars-cov-2 in patients with inflammatory bowel diseases: where do we stand?
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/974d936acac9461db59ea627ff5daff4
work_keys_str_mv	AT philrobintepasse vaccinationagainstsarscov2inpatientswithinflammatoryboweldiseaseswheredowestand AT richardvollenberg vaccinationagainstsarscov2inpatientswithinflammatoryboweldiseaseswheredowestand AT tobiasmaxnowacki vaccinationagainstsarscov2inpatientswithinflammatoryboweldiseaseswheredowestand
_version_	1718411512274485248

Vaccination against SARS-CoV-2 in Patients with Inflammatory Bowel Diseases: Where Do We Stand?

Ejemplares similares